News

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...
Pharmaceutical Technology on MSN2d
CHMP recommends GSK’s Blenrep approval for multiple myeloma treatment
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
pharmaphorum1d
GSK pays $1.2bn for liver drug as it culls TIGIT programme
GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...
Reno Gazette-Journal4d
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
MIAMI, FL / ACCESS Newswire / May 28, 2025 / MIRA Pharmaceuticals ... taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings ...
Boston Scientific to stop heart device sales amid regulatory challenges
Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.
BostonGene: Transforming Cancer Drug Discovery and Development With AI Multiomics
In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...
Insider Media4d
N4 Pharma forms new leadership team featuring “world-class group of consultants”
East Midlands-based biotechnology company N4 Pharma has formed a new senior leadership team featuring consultants in drug ...